Drug Profile
Research programme: ALK2 inhibitors - BioCryst Pharmaceuticals
Alternative Names: BCX 9499Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator BioCryst Pharmaceuticals
- Class Small molecules
- Mechanism of Action ACVR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrodysplasia ossificans progressiva
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Fibrodysplasia-ossificans-progressiva in USA (PO)
- 05 Jan 2018 Preclinical trials in Fibrodysplasia ossificans progressiva in USA (PO)